The role of E-Cadherin expression in primary site of breast cancer

Arch Gynecol Obstet. 2022 Apr;305(4):913-920. doi: 10.1007/s00404-021-06198-1. Epub 2021 Sep 12.

Abstract

Purpose: The tumour's ability to metastasize is the major cause for fatal outcomes in cancer diseases. In breast cancer, aberrant E-Cadherin expression has been linked to invasiveness and poor prognosis.

Method: We assessed expression of E-Cadherin by immunohistochemistry in primary tumour tissue from 125 female breast cancer patients. Staining intensities were analysed using the immunoreactive score (IRS). We investigated E-Cadherin expression and its associations with clinicopathological parameters (age, tumour size, lymph node status, grade, hormone receptors, Her2 Status) as well as with recurrence and survival.

Results: Increased, rather than aberrant E-Cadherin expression was found and was associated with poor outcome (p = 0.046). Our data show an association between elevated E-Cadherin in primary tumour tissue and an unfavourable negative prognosis in patients.

Conclusion: This association was somehow unexpected as loss of E-Cadherin has long been regarded as a prerequisite for development of invasiveness and metastases. Our findings support the notion that E-Cadherin promotes, rather than suppresses, development of metastasis and invasiveness.

Keywords: Breast cancer; E-cadherin; Metastasis; Prognosis; Recurrence.

MeSH terms

  • Antigens, CD / metabolism
  • Biomarkers, Tumor / analysis
  • Breast Neoplasms* / pathology
  • Cadherins* / metabolism
  • Female
  • Humans
  • Immunohistochemistry
  • Lymphatic Metastasis
  • Prognosis

Substances

  • Antigens, CD
  • Biomarkers, Tumor
  • CDH1 protein, human
  • Cadherins